Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Orfadin | nitisinone | Hereditary tyrosinemia type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
Orgovyx | relugolix | Advanced prostate cancer | Active | |||
Orilissa | elagolix | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
Orkambi | lumacaftor/ivacaftor | Cystic Fibrosis, F508del CFTR mutation | Do not reimburse | Complete | ||
Orkambi | lumacaftor/ivacaftor | Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older | Do not reimburse | Complete | ||
Orladeyo | berotralstat | hereditary angioedema (HAE) | Reimburse with clinical criteria and/or conditions | Complete | ||
Osphena | ospemifene | Dyspareunia, vaginal dryness | Reimburse with clinical criteria and/or conditions | Complete | ||
Otezla | Apremilast | Arthritis, psoriatic | List with criteria/condition | Complete | ||
Otezla | Apremilast | Plaque psoriasis | Do not list | Complete | ||
Otezla | Apremilast | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete |